Skip Navigation

European Heart Journal 2001 22(18):1635-1639; doi:10.1053/euhj.2001.2759
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Al-Saady, N.M.
Right arrow Articles by Sopher, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Saady, N.M.
Right arrow Articles by Sopher, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Prothrombotic markers in atrial fibrillation: what is new?

N.M. Al-Saady and M. Sopher

Department of Cardiological Sciences, St. George's Hospital Medical School, London, U.K.

References

  1. Mackstaller LL, Alpert JS. Atrial fibrillation: A review of mechanism, etiology, and therapy. Clin Cardiol. 1997;20:640–650[ISI][Medline]
  2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of atrial fibrillation. The Framingham Study. N Engl J Med. 1982;306:1018–1022[Abstract]
  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Int Med. 1987;147:1561–1564[Abstract]
  4. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persistent dilemmas. Stroke. 1988;19:937–941[Free Full Text]
  5. Odell JA, Blackshear JL, Davies E. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction. Ann Thorac Surg. 1996;61:565–569[Abstract/Free Full Text]
  6. Ezekwitz MD, James KE, Nazarian SM. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators. Circulation. 1995;92:2178–2182[Abstract/Free Full Text]
  7. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GYH. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001;22:1741–1747[Abstract/Free Full Text]
  8. Asakura H, Hifumi S, Jokji H. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coag Fibrin. 1992;3:469–473[ISI][Medline]
  9. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47–51[Abstract/Free Full Text]
  10. Lip GYH, Lip PL, Zarifis J. Fibrin D-dimer and b-thromboglobulin as markers of thrombogensis and platelet activation in atrial fibrillation. Circulation. 1996;94:425–431[Abstract/Free Full Text]
  11. Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Jpn Circ J. 1998;62:837–843[CrossRef][Medline]
  12. Minamino T, Kitakaze M, Sanada S. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation. 1998;98:1721–1727[Abstract/Free Full Text]
  13. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet a-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989;84:92–99[ISI][Medline]
  14. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine and thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol. 1991;115:223–224[Abstract/Free Full Text]
  15. White CW, Kerber RE, Weiss HR, Marcus ML. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res. 1982;51:205–215[Abstract/Free Full Text]
  16. Morillo C, Klein G, Jones D, Guiraudon C. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91:1588–1595[Abstract/Free Full Text]
  17. Sanfilippo AJ, Abascal VM, Sheehan M. Atrial enlargement as a consequence of atrial fibrillation: a prospective echocardiographic study. Circulation. 1990;82:792–797[Abstract/Free Full Text]
  18. Al-Saady NM, Obel OA, Camm AJ. The left atrial appendage: Structure, Function and Role in Thromboembolism. Heart. 1999;82:547–555[Abstract/Free Full Text]
  19. Grimm RA, Stewart WJ, Maloney JD. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterisation by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359–1366[Abstract]
  20. Al-Saady NM, Haven AJ, Davies MJ. The relationship between atrial thromboembolism, endocardial expression of von Willebrand Factor and atrial macrophage infiltration in the fibrillating atrium. Circulation. 2001;:
  21. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications of atrial fibrillation. The Copenhagen AFASAK Study. Lancet. 1989;1:175–179[ISI][Medline]
  22. Arch Intern Med. 1994;154:1449–1457[Abstract]
  23. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154:1443–1448[Abstract]
  24. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322:428–432[Abstract]
  25. Jegaden O, Eker A, Delavahe F. Thromboembolic risk and late survival after mitral valve replacement with the St. Jude Medical Valve. Ann Thorac Surg. 1994;58:1721–1728[Abstract]
  26. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945–1953[Abstract]
  27. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy. Br Heart J. 1995;73:527–533[Abstract/Free Full Text]
  28. Pemerstorfer T, Stohlawetz P, Stummvoll G. Low dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haem. 1998;102:1229–1231[CrossRef][ISI][Medline]
  29. Manning WJ, Silverman DI, Katz SE. Impaired left atrial mechanical function after cardioversion: relationship to the duration of atrial fibrillation. J Am Coll Cardiol. 1994;23:1535–1540[Abstract]
  30. Daoud EG, Marcovitz P, Knight BP. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation. 1999;99:3024–3027[Abstract/Free Full Text]
  31. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in nonrheumatic atrial fibrillation. Heart. 1997;77:407–411[Abstract/Free Full Text]
  32. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–112[Abstract]
  33. Oltrona L, Broccolino M, Merlini PA, Spinola A, Pezzona A, Mannucci PM. Activation of the haemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation. 1997;95:2003–2006[Abstract/Free Full Text]
  34. Lip GYH, Rumley A, Dunn FG, Lowe GDO. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: Effects of cardioversion to sinus rhythm. Int J Cardiol. 1995;51:245–253[CrossRef][ISI][Medline]
  35. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Plasma fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: Evidence of intermediate levels of intravascular thrombogenesis. Am Heart J. 1996;131:724–730[CrossRef][ISI][Medline]
  36. Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet. 1977;349:1565–1566

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
S. Kamath, A. D. Blann, B. S. P. Chin, F. Lanza, B. Aleil, J. P. Cazenave, and G. Y. H. Lip
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy
Eur. Heart J., November 2, 2002; 23(22): 1788 - 1795.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Al-Saady, N.M.
Right arrow Articles by Sopher, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Saady, N.M.
Right arrow Articles by Sopher, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?